Curated News
By: NewsRamp Editorial Staff
May 09, 2025
ABVC BioPharma Secures Patent Protection and $667M Licensing Agreement for Botanical Depression Treatment
TLDR
- ABVC BioPharma secures new patent for MDD treatment, strengthening global IP portfolio and enhancing market competitiveness.
- ABVC's ABV-1504, derived from Polygala tenuifolia, acts as a NET inhibitor, offering a safer, non-addictive long-term treatment for MDD.
- ABV-1504 aims to provide a safer, non-addictive, and better-tolerated long-term treatment for individuals suffering from depression, making the world a better place.
- Japan Patent Office grants new patent protection for ABV-1504, enhancing ABVC's global IP portfolio and market presence in the pharmaceutical industry.
Impact - Why it Matters
This news matters as it highlights ABVC BioPharma's innovative botanical drug platform, providing a safer and more effective treatment option for individuals suffering from depression. The new patent and licensing agreement signify the company's strategic growth and potential global impact in the pharmaceutical market.
Summary
ABVC BioPharma, Inc. announced the Japan Patent Office has granted new patent protection for its Major Depressive Disorder (MDD) candidate, ABV-1504, strengthening the company's global intellectual property portfolio. The compound, derived from Polygala tenuifolia, offers a botanical-based alternative for depression treatment. ABVC also secured a $667M global licensing agreement with AiBtl BioPharma for ABV-1504 and ABV-1505, marking a significant milestone in the company's commercialization strategy.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, ABVC BioPharma Secures Patent Protection and $667M Licensing Agreement for Botanical Depression Treatment
